

20 April 2016

**Deltex Medical Group plc
("Deltex Medical", or "the Company")**

Posting of Annual Report and Notice of AGM

Deltex Medical Group plc (AIM:DEMG), the global leader in oesophageal Doppler monitoring ("ODM"), announces that the Company's Annual Report for the year ended 31 December 2015 were posted to shareholders on 18 April 2016, along with notice of the Company's Annual General Meeting ("AGM"), to be held at the offices of Laytons Solicitors, 2 More London Riverside, London, SE1 2AP, at 11:00am on 12 May 2016.

A copy of the Annual Report and AGM notice are available on the Company's website at <http://www.deltexmedical.com/investor-relations/annual-interim-reports>.

For further information, please contact:-

Deltex Medical Group plc
01243 774 837
investorinfo@deltexmedical.com

Nigel Keen, Chairman
Ewan Phillips, Chief Executive

Jonathan Shaw, Group Finance Director
Barry Curtis, Company Secretary

Nominated Adviser & Broker
Arden Partners plc
Chris Hardie
020 7614 5900

Joint Broker
Zeus Capital Limited
Phil Walker
Dominic Wilson
020 3829 5000

Financial Public Relations
IFC Advisory
Tim Metcalfe
Graham Herring
Heather Armstrong
0203 053 8671

Notes for Editors

Deltex Medical manufactures and markets haemodynamic monitoring technologies. Deltex Medical's ODM is the only technology to measure continuously blood flow in the central circulation in real time. Minimally invasive, easy to set up and quick to focus, the technology generates a low-frequency ultrasound signal, which is highly sensitive to changes in flow and measures them immediately. Deltex has been the only company in the enhanced haemodynamic space to build a robust and credible evidence base proving the clinical and economic benefits of its core technology, ODM. Randomised, controlled trials using Doppler have demonstrated that early fluid management intervention will reduce post-operative complications, reduce intensive care admissions, and reduce the length of hospital stay.

Company goal

ODM is increasingly recognised as a standard of care for patients undergoing major surgery and in critical care. The broader clinical area of haemodynamic management of which ODM is a core constituent is also now becoming widely accepted as an important major new medical modality. Consequently, the Company's focus is on maximising value from the

opportunities presented as enhanced haemodynamic management is adopted into routine clinical practice around the world.

The Company is currently in the implementation phase of achieving this goal in a number of territories worldwide, operating directly in the UK, USA, Spain and Canada and through distribution arrangements in a further 30 countries.

There are over 3,200 monitors installed in hospitals around the world and over 650,000 patients have been treated to date using Deltex Medical's single patient disposable probes.